Initial metastatic kinetics is the best prognostic indicator in stage IV metastatic melanoma

European Journal of Cancer

Volumn 50, Issue 6, 2014, Pages 1120-1124

  Gaudy Marqueste, Caroline ^a   Archier, Elodie ^a   Grob, Anaïs ^a   Durieux, Olivier ^a   Loundou, Anderson ^a   Richard, Marie Aleth ^a   Grob, Jean Jacques ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Kinetics; Melanoma; Prognosis

Indexed keywords

LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; KINETICS; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; TUMOR VOLUME; UNIVARIATE ANALYSIS; VERY ELDERLY;

KINETICS; MELANOMA; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; FEMALE; HUMANS; KINETICS; L-LACTATE DEHYDROGENASE; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; WATCHFUL WAITING; YOUNG ADULT;

EID: 84897104300     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.12.015     Document Type: Article

References (15)

1. J. Villanueva, A. Vultur, and J.T. Lee et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K Cancer Cell 18 6 2010 683 695
2. A. Farolfi, L. Ridolfi, and M. Guidoboni et al. Ipilimumab in advanced melanoma: reports of long-lasting responses Melanoma Res 22 3 2012 263 270
3. C. Ottensmeier, J. Weber, and J.B. Haanen et al. Ipilimumab produces durable objective responses in patients with previously treated, Advanced melanoma: results from a phase III trial Ann Oncol 21 8 2010 abstract 1326P
4. P.A. Ascierto, E. Simeone, D. Giannarelli, A.M. Grimaldi, A. Romano, and N. Mozzillo Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use J Transl Med 28 10 2012 107
5. S. Jang, and M.B. Atkins Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol 14 2 2013 e60 e69
6. C. Ferte, M. Fernandez, and A. Hollebecque et al. Use of tumor growth rate (TGR) to provide useful clinical information in phase I trials and reveal clear drug-specific profiles J Clin Oncol 31 Suppl. 2013 1 [abstr 3010]
7. P.A. Ascierto, E. Simeone, and A.M. Grimaldi et al. Do BRAF inhibitors select for populations with different disease progression kinetics? J Transl Med 11 2013 61
8. M.M. Delaunay, J.M. Amici, and M.F. Avril et al. Traitement chirurgical des metastases pulmonaires du mélanome malin Ann Dermatol Venereol 118 4 1991 287 295
9. Houghton AN, Balch CM. Treatment for advanced melanoma. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ, editors. Cutaneous melanoma, vol. 38. Philadelphia: Lippincott Williams & Wilkins; 1992. p. 470-475.
10. Meyers LM, Balch CM. Diagnosis and treatment of metastatic melanoma. In: Balch CM, Houghton AN, Sober AJ, Soong SJ, editors. Cutaneous melanoma, vol. 22. St Louis: Mo Quality Medical Publishing; 1998. p. 325-345.
11. S.E. Shackney Tumor growth, cell cycle kinetics, and cancer treatment 1993 McGraw Hill New York
12. C. Robert, L. Thomas, and I. Bondarenko et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 26 2011 2517 2526
13. J. Manola, M. Atkins, J. Ibrahim, and J. Kirkwood Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials J Clin Oncol 18 22 2000 3782 3793
14. O. Eton, S.S. Legha, and T.E. Moon et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma J Clin Oncol 16 3 1998 1103 1111
15. C.M. Balch, J.E. Gershenwald, and S.J. Soong et al. Final version of 2009 AJCC melanoma staging and classification J Clin Oncol 27 36 2009 6199 6206